Lancet Rheumato: Dapansutrile Treats Gout Flares

Leuketointerin (IL)-1 beta plays an important role in gout flares, Dapansutrile inhibits NLRP3 inflammation and IL-1 beta activation, and researchers recently examined the safety and efficacy of oral dapansutrile in patients with gout flaresthis study was a clinical study of IIa, with the participation of adult gout flare patients with mono-joint uric acid monosodium crystals, who were randomly treated with 100 mg/day, 300 mg/day, 1000 mg/day, or 2000 mg/day oral dapansutrile treatment for 8 daysThe main results of the study were changes in target joint pain reported by patients from baseline to 3 and from baseline to 7th day,29 patients participated in the study, of which 8 patients received 100 mg of the drug per day, 7 patients received 300 mg of the drug per day, 6 patients received 1,000 mg of the drug per day, and 8 patients received 2,000 mg of the drug per dayFrom baseline examination to the third day, the target joint pain reported by patients in the 100 mg/day group decreased by an average of 52.4%, the 300 mg/day group decreased by 68.4%, the 1000 mg/day group decreased by 55.8%, and the 2000 mg/day group decreased by 57.6%On the 7th day, the target joint pain in the 100 mg/day group decreased by an average of 82.1%, the 300 mg/day group by an average of 84.2%, the average decrease of 68.9% in the 1000 mg/day group, and an average decrease of 83.9% in the 2000 mg/day group compared to the baselineTwenty-five of the 34 patients (73.5 per cent) reported adverse events caused by treatment, the majority of which were metabolic and nutritional disorders (17 (37.8%)) and gastrointestinal diseases (10 (22.2%)During the study period, two serious adverse events occurred, with one patient admitted to hospital on the third day due to gout flare sourness and one patient admitted to hospital 18 days after receiving the last dose of the drug due to coronary artery stenosis, but none of them were related to the study drugstudies have concluded that Dapansutrile is a specific NLRP3 inflammatory inhibitor with satisfactory safety and efficacy in reducing targeted joint pain